Faculty profile

Mark Norman Levine

Back to faculty
Professor EmeritusOncologyMcMaster University

Research

Research areas, by share of publications

Research areas are derived from OpenAlex topics of their publications.

From the 150 most recent of 781 publications.

01

Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial

Wang Y, Donovan EK, Levine MN, Whelan TJ, Swaminath A, Parpia S, Investigators FTLT, Swaminath A, Okawara G, Sur R

Clinical Lung Cancer20261 citations
02

Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma

Metser U, Dayes IS, Parpia S, Eisen AF, Hodgson N, Cil TD, George R, Blanchette P, Arnaout A, Chan A

British Journal of Cancer2026
03

Correction: Prospective study on 18F-FDG PET-CT for staging locally advanced invasive lobular breast carcinoma

Metser U, Dayes IS, Parpia S, Eisen AF, Hodgson N, Cil TD, George R, Blanchette P, Arnaout A, Chan A

British Journal of Cancer2026
04

Reconstructive surgery and immigration status among females with breast cancer

Lovrics O, Kirkwood D, Coroneos CJ, Pond G, Hodgson N, Doumouras AG, Bogach J, Levine M, Parvez E

Canadian Journal of Surgery2026
05

CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.

Lalani A-KA, Pond GR, Siva S, Chu W, Gopaul D, Morgan SC, Basappa NS, Winquist E, Bonert M, Bramson J

Journal of Clinical Oncology2026
06

Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial

Hou Q, Parpia S, Wierzbicki M, Kundapur V, Faria S, Okawara GS, Tsakiridis TK, Ahmed N, Bujold A, Hirmiz K

International Journal of Radiation Oncology Biology Physics2026
07

Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy

Group EBCTC, Braybrooke J, Bradley R, Hills RK, Peto R, Kerr A, Pan H, Clarke M, Dodwell D, McGale P

The Lancet202536 citations
08

OPAR: A Randomized Trial of Partial Breast Irradiation in Five Fractions Once Daily for Early Breast Cancer

Kim D-H, Théberge V, Parpia S, Kong I, Provencher S, Yassa M, Perera F, Lavertu S, Rousseau P, Lee J

Journal of Clinical Oncology20257 citations
09

The Association of Insomnia with Febrile Neutropenia, Leucopenia, and Infection in Women Receiving Adjuvant Chemotherapy for Breast Cancer

Lemelin A, Savard J, Chen M, Shepherd LE, Burnell M, Levine MN, Chen BE, Lemieux J

Cancers20254 citations
10

18F-FDG PET/CT Semiquantitative and Radiomic Features for Assessing Pathologic Axillary Lymph Node Status in Clinical Stage I–III Breast Cancer Patients: A Systematic Review

Hwang A, Rashid S, Shi S, Blew C, Levine M, Saha A

Current Oncology20254 citations
Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for
Subject: Prospective PhD student: Breast Cancer Treatment Studies Dear Professor Levine, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Stereotactic Versus Conventional Radiotherapy in Medically Inoperable Stage I Non–Small Cell Lung Cancer: A Bayesian Reanalysis of the LUSTRE Randomized Trial" (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]
Open in email
Something wrong or missing on this profile? Suggest a correction